BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...

Related Keywords

China ,Israel ,Russia ,United States ,Ukraine ,Russian ,American ,Moran Meir ,John Lacey ,Gloria Biosciences ,Philip Serlin ,Washington University School Of Medicine ,American Society Of Hematology ,Nasdaq ,National Comprehensive Cancer Network ,Linkedin ,Biolinerx Ltd ,Lifesci Advisors ,Columbia University ,Washington University ,Prnewswire Biolinerx Ltd ,Twitter ,Exchange Commission On ,Exchange Commission ,Healthcare Common Procedure Coding System ,Chief Executive Officer ,Orphan Drug Designation ,Orphan Drug ,Hematopoietic Cell ,American Society ,Annual Meeting ,Drug Evaluation ,National Medical Products Administration ,Ductal Adenocarcinoma ,Cell Disease ,Washington University School ,Year Ended ,Kreos Capital ,Private Securities Litigation Reform Act ,Sci Advisors ,